Comparative pharmacokinetics of rifampicin and 25-desacetyl rifampicin in healthy volunteers after single oral dose administration

Farmacia

Volumn 61, Issue 2, 2013, Pages 398-410

  Marchidanu, Daniela ^a   Raducanu, Nicoleta ^a   Miron, Dalia Simona ^a   Radulescu, Flavian Ştefan Radulescu ^a   Anuţa, Valentina ^a   Mircioiu, Ion ^b   Prasacu, Irina ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

25 desacetyl rifampicin; Pharmacokinetics; Rifampicin

Indexed keywords

25 DESACETYL RIFAMPICIN; DRUG METABOLITE; RIFAMPICIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDIVIDUALIZATION; MALE; NORMAL HUMAN; PLASMA HALF LIFE; SINGLE DRUG DOSE;

EID: 84875976213     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Barakat MT, Scott J, Hughes JM, Walport M, Calam J, Friedland JS, Ind PW, McKenna C: Grand rounds-Hammersmith Hospital. Persistent fever in pulmonary tuberculosis. BMJ 1996, 313(7071):1543-1545
2. Cohn DL, Bustreo F, Raviglione MC: Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997, 24 Suppl 1:S121-130
3. Ellis ME, al-Hajjar S, Bokhari H, Hussein Qadri SM: High proportion of multi-drug resistant Mycobacterium tuberculosis in Saudi Arabia. Scand J Infect Dis 1996, 28(6):591-595
4. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C et al: Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001, 344(17):1294-1303
5. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P et al: Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998, 338(23):1641-1649
6. Bhatt AD, Vaz JA, Padgaonkar KA: Clinical relevance of reduced bioavailability of rifampicin. J Assoc Physicians India 1998, 46(8):729-731
7. Grange JM, Winstanley PA, Davies PD: Clinically significant drug interactions with antituberculosis agents. Drug Saf 1994, 11(4):242-251
8. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M: Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985, 63(23):1205-1211
9. Zhang JN, Liu XG, Zhu M, Chiu FC, Li RC: Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 1998, 10(5):354-359
10. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P: Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006, 50(4):1170-1177
11. Becker C, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM: Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. J Pharm Sci 2009, 98(7):2252-2267
12. Shah VP, Bansal S: Historical perspective on the development and evolution of bioanalytical guidance and technology. Bioanalysis 2011, 3(8):823-827
13. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML et al: Bioanalytical method validation--a revisit with a decade of progress. Pharm Res 2000, 17(12):1551-1557
14. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R: Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 2010, 54(3):1068-1074
15. Gurumurthy P, Raghupati Sarma G, Jayasankar K, Thyagarajan K, Prabhakar R, Muthusethupathi MA, Sampathkumar P, Shivakumar S: Single-dose pharmacokinetics of isoniazid and rifampicin in patients with chronic renal failure. Ind J Tub 1992, 39:221-228
16. Lesko LJ: Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007, 81(6):807-816
17. DrugBank - Open Data Drug & Drug Target Database. Available at: http://www.drugbank.ca. Last accessed: July 15th, 2012
18. Prasacu I, Mircioiu C, Sandulovici R, Enache F: Release of metoprolol from solid dosage forms. Choice and validation of theoretical model. Farmacia 2009, 57(1):89-98
19. Sandulovici R, Prasacu I, Mircioiu C, Voicu V, Medvedovici A, Anuta V: Mathematical and phenomenological criteria in selection of pharmacokinetic model for M1 metabolite of pentoxyphylline. Farmacia 2009, 57(2):235-246
20. Tvrdonova M, Dedik L, Mircioiu C, Miklovicova D, Durisova M: Physiologically motivated time-delay model to account for mechanisms underlying enterohepatic circulation of piroxicam in human beings. Basic Clin Pharmacol 2009, 104(1):35-42
21. Peloquin CA: Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002, 62(15):2169-2183
22. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T et al: Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Resp Crit Care 2003, 167(10):1341-1347
23. Panchagnula R, Agrawal S, Kaur KJ, Singh I, Kaul CL: Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol. Int J Tuberc Lung D 2000, 4(12):1169-1172.